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1 in 15 Americans has experienced peripheral nerve injury as a result of trauma or 
medical disorders1. While nerve tissue has the ability to regenerate naturally, the formation 
of scar tissue and an inflammatory response after injury can result in incomplete regrowth. 
Symptoms such as limb paralysis and chronic neuropathic pain due to cell death can be 
permanent2. 
In the event of a traumatic nerve injury, cell death is immediate. Axons and myelin 
degenerate 1-2 days after the injury in a process known as Wallerian degeneration3. Schwann 
cells then migrate to the site to begin the breakdown and phagocytosis of myelin and cell 
debris. After this step, they begin to proliferate as a support mechanism; this proliferation is 
essential for axonal regeneration. Schwann cells line the endoneurial tube in an elongated 
formation called bands of Bungner. They express myelin-associated proteins and neurotrophic 
factors to increase proliferation4. Studies show that axons respond chemotactically to these 
neurotrophic factors and grow in the direction of expression5. Therapies that make use of the 
Schwann cell’s ability to guide growth through the protein expression gradient show promise 
for this reason. One of the factors expressed by Schwann cells, myelin-associated glycoprotein 
(MAG), has a few key roles in the regeneration pathway. In addition to myelinating regrowing 
axons, MAG is responsible for signaling macrophages to leave the area after the initial injury 
to reduce inflammation and allow for unimpeded growth. However, the high expression levels 
of MAG and other neurotrophic factors after injury are transient and decline sharply over the 
regeneration period7. Myelin Protein Zero (MP0) is also a key myelinating factor, especially in 
the case of adult axon regeneration. Because it is specifically involved in formation of the 
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myelin sheath, MP0 is usually upregulated after MAG begins initial myelination7. Schwann 
cells are the most common glial cell type in the peripheral nervous system and play an outsize 
role in regulating regeneration. Their 
denervation is a limiting factor for 
axonal regeneration and ultimately 
functional recovery, as well as a 
potential therapeutic target2.  
Without guidance across the 
nerve gap formed in peripheral nerve 
injuries, axons regrow disorganized, 
which can lead to eventual muscle 
atrophy. Ideally, the separated nerve 
endings are sutured together, but this 
cannot be done if the gap is too large 
and would cause significant tension on 
the nerve. The standard treatment for 
substantive nerve gaps involves 
grafting a nerve segment taken from a 
separate area in the patient’s body, 
usually from expendable sensory nerves. While using the patient’s own tissue (an autograft) 
prevents the immune response, the process requires multiple surgeries, and the donor site 
requires repair3. Furthermore, despite rapid advances in surgical methods, the nerves rarely 
Figure 1. Regeneration process of neurons after a 
traumatic force injury. The initial Wallerian degeneration 
extends in both directions. Figure taken from St. 
Vincent’s Hospital research study1. 
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reach complete functional recovery1. Artificial scaffolds can serve as effective alternatives to 
nerve grafts. These scaffolds generally consist of an outer guidance channel and may also 
include elements within the channel to promote regeneration. The materials used to 
construct these scaffolds must have similar mechanical properties to nerves, prevent an 
immune response, and allow for oxygen diffusion in the area in addition to cell proliferation8. 
They must also be biodegradable and disappear when the area is healed in order to prevent 
pressure once the nerve has grown back. 
Collagen, a protein that makes up most of the connective tissue in the body, is a 
promising candidate for various tissue engineering applications because of its 
biocompatibility4. To date, collagen is the only clinically approved biopolymer on the market 
for peripheral nerve regeneration. It is used for neuroregenerative therapies because it can 
support nerve regeneration at a damaged site and biodegrade when it is no longer needed, 
thereby avoiding an immune reaction5. In order to generate the mechanical strength needed 
to support nerve regeneration, collagen nanofibers can be created through electrospinning. 
Electrospinning uses electrical energy to create thin nanofibers out of a solution. This process 
enhances the mechanical properties of the original material, and the resulting fibers are 
porous, allowing for diffusion as well as the addition of growth factor to the material3. These 
fibers also create a 3-dimensional environment that resembles the native extracellular matrix 
of the peripheral nerve microenvironment. The high surface area of the fibers has been linked 
to better cellular attachment. Because of this, electrospun scaffolds demonstrate significant 
functional recovery. Previous studies show that Schwann cells in particular adhere well to and 
elongate along electrospun fibers, forming structures similar to bands of Bungner. The fiber 
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orientation can also guide growth in a certain direction, for example from the proximal to the 
distal nerve ending. Furthermore, electrospinning allows better control over material 
properties such as the porosity and degradation rate. This is done by altering the solution 
concentration and potentially the ratio if the material in question is a composite. As a natural 
polymer, collagen has a rapid degradation rate, so mixing it with a synthetic polymer to create 
a composite can help with stability9. The first 10-12 weeks after injury are crucial for axonal 
regeneration and functional recovery, so the conduit should only begin degradation after that 
point. 
Polymeric nanoparticles protect therapeutic factors and deliver them efficiently to the 
target site. Poly(lactic-co-glycolic acid) is a composite made of two polymers: polylactic acid, 
or PLA, and poly(glycolic acid), or PGA. PLGA degrades slowly using a hydrolysis mechanism, 
meaning these microparticles are also highly biodegradable. The precise degradation rate of 
the material as well as other characteristics like permeability can be controlled by altering the 
PGA:PLA ratio. Polymeric microparticles are often used as drug carriers because of their 
efficiency and biocompatibility. PLGA microspheres in particular can prevent drug 
degradation, prolong release, and reduce toxicity10. 
Another extremely biocompatible polymer used extensively in peripheral nerve 
regeneration research is alginate. As a natural biopolymer, alginate mimics the structure of 
the extracellular matrix (ECM) leading to low toxicity, but it also very quickly degrades. This 
can be remedied using a number of modifications, most notably by chemically coupling Arg-
Gly-Asp (RGD) peptides, forming RGD-alginate in the process8. This material has been used in 
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drug and immune cell targeting in the past, and shows promise for microparticle drug delivery 
in the context of the peripheral nervous system. 
A potential growth factor to be used in conjunction with the nerve conduit is 
Neuregulin 1 (NRG1), a protein involved in signaling for the repair of damaged nerves. While 
this protein has many different isoforms with varying capabilities, this study will focus on 
NRG1 Type III, also known as Sensory and Motor-neuron Derived Factor (SMDF). SMDF binds 
to Schwann cell receptors and kicks off a signal transduction pathway that promotes 
myelination, the formation of a sheath around the axons in a nerve. Myelin sheaths protect 
the axon and have been shown to increase conduction velocity in regenerating nerves11. SMDF 
is normally a transmembrane protein, but it can be delivered as a soluble protein and trigger 
the same increase in myelin expression. However, this reaction is dose-dependent, so 
controlled release from the conduit and the effect of dosage on nerve cells must be elucidated 
in order to assess the effects of SMDF within the peripheral nervous system. The incorporation 
of a drug delivery mechanism into a nerve conduit such as the microparticles mentioned 
above would allow for extended drug release over time. The effects of SMDF can be compared 
to other neurotrophic factors in order to accurately assess the efficacy of this potential new 
drug candidate. Nerve growth factor (NGF) and glial cell line-derived neurotrophic factor 
(GDNF) are two proteins that have been previously used in experimental trials for peripheral 
nerve regeneration. Both are expressed naturally by Schwann cells after injury. NGF has been 
proven to prevent axonal degeneration and GDNF promotes myelination5. Based on 
preliminary studies, incorporating SMDF into electrospun collagen nerve guidance channels 
will result in enhanced cell and tissue growth as well as improved functional recovery. 
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Determining the efficacy of NRG1 in the nerve repair process is crucial to further elucidating 
the pathways necessary for tissue regeneration as well as potentially providing a better 
therapeutic avenue for peripheral nerve injuries. 
Methodology and Expected Outcomes: 
The in vivo experiments conducted focus on the effects of SMDF directly applied to Schwann 
cells, the nerve cells responsible for much of the regeneration response. Cell culture was 
performed on S16 cells, an immortalized Schwann cell line taken from the sciatic nerve in rats. 
S16 cells resemble early Schwann cells as they prepare to myelinate7. The cells were cultured 
under standard cell culture conditions (a humidified, 37°C, 5% CO2/95% air environment) and 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum, 1% L-glutamine, and 1% penicillin−streptomycin solution. Cells were passaged 
into 96-well plates at a density of 10,000 cells per well to perform drug dosage experiments. 
This included both flat-bottomed plates treated with laminin, a key nervous system ECM 
protein, as well as plates precoated with aligned poly-L-lactic acid fibers for 3D cell culture 
(Mimetix). They were then dosed with 1, 10, and 100 ng/ml of SMDF in addition to complete 
culture media. In addition, there was a negative control group receiving media without any 
growth factor and two positive control groups receiving 1, 10, and 100 ng/ml of Nerve Growth 
Factor (NGF) and Glial cell line-Derived Neurotrophic Factor (GDNF). The experiment was 
performed in triplicate and the media was replenished daily. After 3 days, the cells were fixed 
in 10% formalin.  
The fixed cells underwent immunostaining for identification of myelin-associated factors 
Myelin Protein Zero (MP0) and MAG. Cell imaging was performed using the Cytation 5 and 
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fluorescence of each well was quantified. This experiment was essential for determining the 
optimal dosage of SMDF that stimulates significant myelination in Schwann cells. Presumably, 
myelination will increase with dosage up to a certain point at which high dosages will start 
inhibiting myelination. 
After determining 
the best dosage, 
SMDF was loaded 
into microspheres, 
mixed with alginate 
hydrogel, and then 
incorporated into a 
nerve conduit (Fig. 
2). This conduit was primarily composed of collagen along with poly-ε-caprolactone (PCL) to 
provide more mechanical strength and longer degradation time, both from Sigma-Aldrich. 
Collagen was lyophilized and then solubilized in HFP using previously detailed methods, after 
which electrospinning occurred9. Electrospun fiber diameters were 1 um in cross-sectional 
diameter, a standard size that was produced by altering concentration of collagen and PCL 
during electrospinning. Formation of PLGA microspheres and RGD-alginate hydrogel were 
formed using previously detailed methods10. To analyze growth factor release over time, the 
drug-loaded conduit would be submerged in phosphate-buffered saline (PBS) and placed on 
a rotary shaker at 37°C, mimicking body temperature. The amount of drug released into 
solution would be quantified at 1, 3, 7, 14, 21, and 28 days using an enzyme-linked 
 
Figure 2. The conduit, consisting of electrospun collagen, contains microspheres containing 
SMDF, which allows for controlled release of growth factor over time. These  microspheres 
are situated within alginate hydrogel to prevent immediate release of SMDF. This figure 
shows the hypothetical placement of the conduit at the site of a nerve gap. 
 
Distal Nerve Proximal Nerve 
- SMDF Proteoliposomes 
- RGD-Alginate 
Electrospun Conduit 
1 cm Gap 
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immunosorbent assay (ELISA) designed to detect SMDF. The biodegradability of the conduit 
within the body can be estimated by placing the conduits in an aqueous PBS solution 
containing 0.1% collagenase. The time taken to fully degrade the collagen conduit both with 
and without SMDF will be recorded. The drug release profile is expected to be a logarithmic 
curve, with an initial “burst” of growth factor release after the first day preceding a gradual 
decrease in growth factor released over time. The degradation rate is expected to be 
comparable to the release rate; ideally, the conduit fully degrades only when there is little to 
no SMDF left in the device. In the future in vivo studies would be conducted to view the effects 
of the device in an animal model.  
Results: 
Figure 3 shows data collected from the 96-well 
flat plate trial. When levels of Myelin Protein 
Zero (MP0) and Myelin Associated Glycoprotein 
(MAG) are quantified through cell imaging, cells 
treated with each growth factor show 
comparable myelination. The negative controls 
show lower myelination across the board. 
GDNF shows increasing myelination with 
increasing concentration. NGF shows some 
decrease in myelin expression at concentrations 
of 100 ng/ml, indicating some cytotoxicity at this 
high dosage. The experimental SMDF groups 
Figure 3. Myelination increases due to SMDF are 
comparable to standard nerve growth factors. 
Staining intensity was analyzed in single cells to 
compare myelination density between groups. Two 
different myelin markers were used; MAG+ staining 
indicates the development of a myelin sheath while 
MP0+ is only present in fully formed myelin sheaths. 
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show increased myelination over the negative control, but they also show gradually 
decreasing myelination as concentration of the growth factor increases. This may imply some 
toxicity at higher levels, similar to NGF. 
Looking at the microscopy images in Figure 4 further elucidates the mechanisms that may be 
occurring. Regardless of treatment, some wells have much higher myelin expression levels 
than others in the same experimental group. These results may imply that while growth 
factors aid in myelin expression, the cells themselves eventually start signaling to each other 
once they reach a certain myelin threshold, after which all cells in the area start expressing 
Figure 4. Fluorescent microscopy images of Schwann cells on flat 96-well plates (n=3) illustrate significant 
myelination. Cells underwent four different treatments: a control group with no growth factor treatment; NGF, a 
growth factor involved in many different nerve regulatory pathways; GDNF, which promotes neuronal cell survival; 
and SMDF, the protein of interest. Within these treatment groups, each growth factor was administered in trials of 
1, 10, and 100 ng/ml to visualize effects dependent on drug dosage. Primary staining was conducted with anti-
myelin antibodies, and secondary staining was conducted using fluorescent antibodies.  
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high levels of myelin. Future therapies and further research should focus on identifying this 
threshold and the factors that encourage cells to meet it. Overall, SMDF seems to show the 
most consistent (though not the highest) levels of expression compared to the positive and 
negative controls.  
  
 
Interestingly, the experiments conducted on the fiber plates (Fig. 5) show significantly 
more variability in their results. The formation of the bands of Bungner is clear as the cells 
formed aligned myelin sheaths. However, there appeared to be no significant difference in 
myelin expression across the board, as even the positive controls showed less myelination than 
the negative control. 
Figure 5. Fluorescent microscopy images of Schwann cells on fiber plate 96-well plates. The experimental 
groups, dosages, and primary antibodies used were the same as in Figure 3. The unique fiber alignment of the 
wells illustrate the natural arrangement of Schwann cells in bands of Bungner.  
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Discussion and Conclusion: 
Peripheral nerve regeneration involves multiple cellular pathways. Schwann cells 
especially play an important role as the key instigators of phagocytosis of myelin debris and 
remyelination. Optimizing nerve guidance channels by incorporating drugs that target Schwann 
cells—in this case SMDF—is a novel way to improve outcomes after traumatic injury.  
Cell culture and immunostaining methods indicated a significant increase in myelination 
after treatment with SMDF over the negative control. While the positive controls (NGF and 
GDNF) primarily served to confirm the success of the assays, SMDF showed comparable results 
with respect to the positive controls regardless. This implies promise in using SMDF as a 
potential drug candidate in further peripheral nerve regeneration experiments. 
In terms of testing SMDF on fiber plates, results were mixed. This may be due to the 
fundamental difference in structure of the flat and fiber plate assays. Fiber plates allowed for 
formation of thin elongated myelin sheaths, very similar to the myelination process in vivo. 
Because this 3D morphology was not able to arise on the flat plate assays, this may have 
resulted in continuous upregulation of myelin-associated factors and therefore a brighter 
signal. Schwann cells may perform different processes on fiber plates with different myelination 
cues. Once the correct 3D morphology has been formed, there is no longer any need to 
upregulate myelination. Further trials must be conducted to determine the true mechanisms 
behind myelination in both 3D and 2D cell culture. 
In addition to repetition of the flat and fiber plate experiments, nerve conduit analysis 
must be performed in order to ascertain the optimal composition and drug concentration for 
remyelination in vivo. This involves biodegradability assays and controlled release experiments 
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(ex. ELISA). As mentioned before, the most integral nerve regeneration occurs up to 10-12 
weeks after peripheral nerve injury, meaning that an effective conduit must last at least 10 
weeks before beginning to degrade1. The degradation rate is also essential to determine, as the 
conduit must degrade quickly enough to avoid blocking the final stages of axon regrowth, which 
would necessitate a second surgery. Controlled release trials must also last 10-14 weeks, as the 
sharp dropoff in myelin regenerating factors is ultimately what leads to incomplete 
regeneration in clinical cases. These experiments would eventually give way to in vivo 
experiments, a common one being severing the sciatic nerve in rat models and implanting the 
drug delivery conduit over a period of weeks to months. This treatment would be compared to 
a conduit implanted without growth factor to determine the effects on regeneration through 
immunostaining, as well as functional recovery over time (carried out using behavioral tests and 
electromyogram analysis). 
Peripheral nervous system injuries drastically decrease patient quality of life, often 
leading to chronic pain and disability. Current treatment methods fall short of basic functional 
recovery standards, sometimes leaving patients paralyzed for life1. Mitigating morbidity and 
lifelong disability is crucial to advancing the field of peripheral nerve regeneration, and carries 
implications for regeneration within the central nervous system as well. We must aim to 
discover more reliable treatments beyond autografts to further advance the fields of medicine 
and neuroscience.  
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